Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Clements

Showing results (451-460 of 462) with videos related to

Pageof 47
Sort By:
Arthritis and Rheumatism|April 1, 2009
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trialDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Design and Synthesis of Novel, Selective GPR40 AgoPAMsChristopher W Plummer, Matthew J Clements, Helen Chen, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
Proceedings. Biological Sciences|April 17, 2024
Unconventional life history in a migratory shorebird: desegregating reproduction and migrationColby R Slezak, Erik J Blomberg, Amber M Roth, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Arthritis Care & Research|November 5, 2011
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exerciseJaap Fransen, Sindhu R Johnson, Frank van den Hoogen, et al.
The Journal of Chemical Physics|May 10, 2020
The ONETEP linear-scaling density functional theory programJoseph C A Prentice, Jolyon Aarons, James C Womack, et al.
Studies in Health Technology and Informatics|September 14, 2004
Kaiser Permanente's Convergent Medical TerminologyRobert H Dolin, John E Mattison, Simon Cohn, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
Pageof 47

Showing results (451-460 of 462) with videos related to

Sort By:
Pageof 47
Arthritis and Rheumatism|April 1, 2009
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trialDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Design and Synthesis of Novel, Selective GPR40 AgoPAMsChristopher W Plummer, Matthew J Clements, Helen Chen, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
Proceedings. Biological Sciences|April 17, 2024
Unconventional life history in a migratory shorebird: desegregating reproduction and migrationColby R Slezak, Erik J Blomberg, Amber M Roth, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Arthritis Care & Research|November 5, 2011
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exerciseJaap Fransen, Sindhu R Johnson, Frank van den Hoogen, et al.
The Journal of Chemical Physics|May 10, 2020
The ONETEP linear-scaling density functional theory programJoseph C A Prentice, Jolyon Aarons, James C Womack, et al.
Studies in Health Technology and Informatics|September 14, 2004
Kaiser Permanente's Convergent Medical TerminologyRobert H Dolin, John E Mattison, Simon Cohn, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
Pageof 47